NCT00348296View on ClinicalTrials.gov

Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Scleroderma, Systemic
Interventions
DRUG

High-dose intravenous immunoglobulin (Venoglobulin-IH)

Trial Locations (1)

852-8501

Nagasaki University, Nagasaki

Sponsors
All Listed Sponsors
lead

Benesis Corporation

INDUSTRY

NCT00348296 - Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis | Biotech Hunter | Biotech Hunter